CD4 + cell depletion accelerates dendritic cell migration and enhances resident dendritic cell proliferation in tumor-draining lymph nodes Authors: Taiki Moriya, Mayuko Hashimoto, Mizuki Ueda, Tatsuya Aoyagi, Ayako Kawaguchi, Kentaro Takahashi, Kobayashi Tsukasa, Kazuki Doi, Hiroaki Hemmi, Tsuneyasu Kaisho, Satoshi Ueha, Koji Matsushima, Yutaka Kusumoto, Tatyana Chtanova, Michio Tomura Published: 2026 ABSTRACT ABSTRACTDepletion of CD4+ cells during an anti-tumor immune response promotes tumor regression and accelerates proliferation of tumor-antigen-specific CD8+ T cells in draining lymph nodes (dLNs). However, the effect of the depletion on inter-organ kinetics of antigen presentation and qualitative changes in dendritic cells (DCs) are not yet understood. Here, we established a novel approach for simultaneous detection of cellular movement and cell cycle phase in vivo by KikGR/Fucci mice and used it to examine migratory and LN resident DC (LNDC) dynamics after CD4+ cell depletion. We found that CD4+ cell depletion enhanced migration of CD11c+ MHC class IIhigh migratory DCs from tumor to dLNs and induced activation-associated phenotypic changes, such as increased MHC class II expression. Despite reduced overall cellularity in tumor dLNs, LNDC numbers were relatively maintained. Within the LNDC compartment, CD4 depletion increased the relative abundance of a CD8α+CD11b+ subset and promoted influx and cell-cycle activity among newly recruited LNDCs. Publicly available single-cell RNA sequencing data further delineated ligand–receptor expression relationships, including Flt3l–Flt3 and Csf2–Csf2ra/Csf2rb axes, within tumor dLNs. These findings reveal remodeling of DC migration, activation, and LNDC turnover within tumor dLNs in the context of CD4+ cell depletion, which enhanced anti-tumor immunity. Introduction Immune therapies, such as checkpoint inhibitors, have delivered remarkable successes for patients with some advanced and metastatic cancers. 1 Other approaches to activating the anti-tumor immune response via cytokines or depletion of immunosuppressive cells are currently being investigated. 2 We and others 3‐6 have shown that monoclonal antibody (mAb) mediated depletion of CD4+ cells suppressed tumor growth in mice. This correlated with enhanced antigen-specific and antigen-dependent CD8+ T cell proliferation in the tumor-draining lymph nodes (dLNs) and higher recruitment of PD-1+ CD8+ T cells to tumors. 7 Moreover, anti-CD4 mAb treatment induced expansion of the CD8+ T cell receptor (TCR) repertoire in tumors, dLNs, and peripheral blood. 8 The first-in-human clinical trial of the anti-CD4 antibody, IT-1208, led to a transient depletion of CD4+ cells and subsequent replacement of CD4+ and CD8+ T cell clones in the blood of cancer patients. 8 In addition, anti-CD4 and anti-PD-L1 mAb treatment induced expansion of the tumor-reactive CD8+ T cell TCR repertoire in the polyclonal fraction of dLNs and tumors. However, depleting migratory dendritic cells (DCs) reversed this effect. 9 These findings suggest that tumor antigen-bearing DCs in dLNs are crucial for driving tumor-reactive CD8⁺ T cell responses, which likely underlie the augmented anti-tumor immunity induced by CD4⁺ cell depletion. Therefore, a detailed characterization of dendritic cell subsets and their dynamics in tumor-dLNs is essential to elucidate the mechanisms by which CD4⁺ cell depletion amplifies anti-tumor immunity. There are two main pathways for CD8+ T cell activation in LNs. The direct presentation pathway is mediated primarily by cross-presenting migratory conventional DC1s (cDC1s). They capture tumor antigens in tumors and migrate to the dLNs 10‐12 where they present tumor antigen-derived peptides on MHC class I molecules to CD8+ T cells. In addition, migratory cDC2s, which have a high antigen-carrying capacity 13 can also mediate CD8+ T cell activation via the direct presentation pathway. 14 , 15 The second pathway involves indirect presentation, where lymph node (LN)-resident DCs (LNDCs) acquire tumor antigens from migratory cDC1 and cDC2 and present them to CD8+ T cells. 15 , 16 Importantly, daughter DCs generated by cell division present antigens captured by the parent DC. This contributes to prolonged antigen presentation, 17 suggesting that proliferation of DCs in the dLN is important for amplifying the anti-tumor immune response. cDC1 LNDCs have a higher capacity to induce anti-tumor CD8+ T cells compared to cDC2 LNDCs. 15 Therefore, to induce a more effective anti-tumor immune response, it is necessary to understand DC migration between tumors and dLNs and DC turnover within dLNs. Previously, we found that immunogenic tumor cell death induced egress of migratory DCs from tumors to the dLNs and proliferation of anti-tumor CD8+ T cells. 18 In contrast to migratory DCs, the dynamics of LNDCs during anti-tumor immune responses are yet to be elucidated. Here we investigated immune cell dynamics in vivo using a dual reporter mouse line expressing photoconvertible fluorescent protein Kikume Green-Red (KikGR) 13 , 19 , 20 and the fluorescent ubiquitination-based cell cycle indicator (Fucci). 21 , 22 Using these reporters, we established a new approach for simultaneous detection of cellular movement and cell cycle phase in vivo (KikGR/Fucci system), and uncovered migratory DC and LNDC dynamics after CD4+ cell depletion. Materials and methods Mice Male and female 13–30-week-old KikGR (for real-time PCR) and KikGR/Fucci (for flow cytometry) mice were used in this study. KikGR and Fucci mice were originally generated and have been bred and maintained in our laboratory. KikGR/Fucci mice were generated by mating KikGR mice 13 , 21 and Fucci-transgenic mice. 21 , 22 C57BL/6 mice were obtained from Japan SLC, Inc. All mice were bred in specific pathogen-free facilities and maintained in groups of 3–6 per cage under standard temperature-controlled conditions that followed a 12 h light and 12 h dark cycle at Osaka Ohtani University. The mice were all acclimated to the conditions of the study at least 1 week prior to the experiments. Animals in the same cage were separated, and each treatment was carried out. All experimental procedures were approved by the Institutional Animal Care and Use Committee of Osaka Ohtani University Faculty of Pharmacy (1501, 2101, and 2606). Mice were euthanized by CO₂ inhalation followed by cervical dislocation, in accordance with the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals. With these procedures, the plan was to euthanize the mice as a humane endpoint if a drop in body temperature or other symptoms were observed, but no mice met this requirement. In total, 100 mice were used in this study. This study has adhered to ARRIVE guidelines. Cell lines Colon adenocarcinoma cell line MC38 (RRID: CVCL_B288) was maintained in culture medium consisting of RPMI-1640 medium (Sigma-Aldrich, R8758) supplemented with 10% (v/v) heat-inactivated bovine calf serum (Hyclone, SH30073), 1% (v/v) Penicillin-Streptomycin-Glutamine mixed solution (NACALAI TESQUE, INC., 06168-34), 10 mmol/L HEPES buffer solution (NACALAI TESQUE, INC., 17557-94) and 1% (v/v) non-essential amino acids solution (NACALAI TESQUE, INC., 06334-56). For tumor inoculation, MC38 cells were harvested and single-cell suspensions of 2 × 106 cells/100 µL were inoculated intradermally in the abdominal skin. Photoconversion and surgical procedures Six days after tumor inoculation, tumors or inguinal LNs were photoconverted as described previously. 13 , 18 , 20 Briefly, KikGR/Fucci mice were anesthetized by the inhalation of 2% isoflurane (Zoetis), and the skin was opened with minimal incision to gently exteriorize the target tissue and minimize mechanical stress. Luminal side of tumors or LNs was exposed to violet light (Tumor: 120 s, 436 nm, 200 mW/cm2, LN: 480 s, 436 nm, 100 mW/cm2) using SP500 spot UV curing equipment with a 436 nm bandpass filter (USHIO). During photoconversion, skin around tumors or LNs was protected from light with aluminum foil. After violet light irradiation, the abdominal wall was closed by suturing. To keep exposed tissues moist during exposure to light, warmed phosphate-buffered saline (PBS) was applied to the region of photoconversion. Cell isolation Cell suspensions from tumors and LNs were prepared as described previously. 18 , 20 Briefly, for tumor infiltrating cell preparation, tumors were finely dissected in RPMI 1640-medium containing 300 U/mL of collagenase from C. Histolyticum (Sigma-Aldrich, C0130), and 1 mg/mL of dispase II (Roche, 4942078001). After mincing with scissors, tumors were incubated in the same solution for 30 min at 37 °C. After adding 2000 U/mL of DNase I (Calbiochem, 260913), cell suspensions were incubated for 15 min at 37 °C and filtered through a cell strainer. For LNs, cells were extruded into RPMI 1640-medium containing 100 U/mL of collagenase type IV (Worthington, LS004188) and 2000 U/mL of DNase I and incubated for 15 min at 37 °C. After adding 0.5 M EDTA, cell suspensions were filtered through a cell strainer. Antibodies and flow cytometry Fluorochrome-conjugated mAbs were obtained from BD Bioscience, eBioscience, or BioLegend as specified in Supplementary Table 1. For flow cytometric analysis, cells were washed with Dulbecco's PBS containing 2% bovine calf serum and 0.02% sodium azide. Next, cells were incubated with 2.4G2 hybridoma culture supernatant to block Fc binding, then stained with fluorochrome-conjugated mAbs for 15 min at 4 °C, and then cells were analyzed using an SP6800 (SONY) or, where indicated in the figure legends, a Cytek Northern Lights 3000 (Cytek Biosciences). Flow cytometry data were analyzed using FlowJo software (Tree Star, RRID: SCR_008520). The number of cells in each cell subset of the LNs was calculated by multiplying the total number of cells by the frequency of each cell subset obtained by flow cytometric analysis. Primers and real-time PCR Total RNA isolated from tumor dLNs of tumor-bearing mice with TRIzolTM reagent (Thermo Fisher Scientific, 15596026) according to instructions was reverse transcribed into cDNA using TaKaRa PrimeScript RT Master Mix (Takara Bio Inc., RR036A) in a T100 thermal cycler (BIO-RAD) following the manufacturer's procedure. Obtained cDNA was subjected to real-time PCR on a CFX96 Touch real-time PCR analysis system (BIO-RAD) using the primers listed in Supplementary Table 2 and TB Green Premix Ex Taq II (Takara Bio Inc., RR820) following the procedure described in the manual. Expression of Flt3l and Csf2 mRNA was normalized by the geometric mean of Ubc and Rpl13a. Reagents and treatment In some experiments, tumor-bearing mice were intraperitoneally treated with 200 µg of anti-CD4 mAb (Clone: GK1.5), anti-CD8β mAb (Clone: 53-5.8), or vehicle (PBS) 4 d after tumor inoculation. PBS control was chosen to avoid Fc-mediated effects. Mice in the same cage were assigned to each reagent treatment group using simple randomization, and the order of treatments was randomized to minimize the potential confounder. Public scRNA-seq data acquisition and analysis Publicly available single-cell RNA sequencing data from tumor dLNs were analyzed to provide supportive transcriptional context for ligand–receptor expression. The dataset (EMBL-EBI Single Cell Expression Atlas; accession E-EHCA-2, “Melanoma infiltration of stromal and immune cells”) 29 was processed using Seurat. LN-derived cells were selected based on original annotations, and dendritic cell populations were summarized as cDC1 and cDC2 according to standard nomenclature. Gene expression was quantified using log-normalized values, and cell populations represented by fewer than 30 cells were excluded from analysis. Data visualization was performed using dot plots and violin plots. Statistical analysis Samples in which tumors were inoculated subcutaneously were excluded. One result was excluded due to this criterion. All other data were included in the analysis without excluding outliers. The researchers who performed the treatment and those who performed the analysis were separated. Comparisons between two groups were performed using the Mann–Whitney U test. For multiple comparisons involving four groups, the Kruskal–Wallis test followed by Dunn's multiple comparisons test was used. All tests were done using GraphPad Prism version 9.0 (GraphPad Software, RRID: SCR_002798). Data in bar graphs represent means ± SEM. p values of less than 0.05 were considered to be statistically significant and labeled: *, p < 0.05; **, p < 0.01; and ***, p < 0.001. Results A novel approach for simultaneous detection of cellular movement and cell cycle phase in vivo Photoconvertible fluorescent protein, KikGR is green prior to photoconversion (KikGR-Green) but can be switched to red (KikGR-Red) when exposed to violet light. This property enables in situ photo-labeling in vivo and investigation of cell migration by quantitating KikGR-Red cells at sites that are distal to the site of photoconversion. 13 , 21 Cells in Fucci mice express mAzami-Green (mAG) in the S/G2/M phase of the cell cycle, and mKusabira-Orange2 (mKO2) in the G0/G1 phase, enabling cell cycle phase analysis. 22 We generated KikGR/Fucci mice that co-express KikGR and Fucci to simultaneously evaluate the effects of CD4+ cell depletion on cell dynamics, such as migration and proliferation of DCs. Due to the partial spectral overlap in the emission peaks of KikGR-Green and mAG, as well as KikGR-Red and mKO2, it is difficult to differentiate between these fluorescent proteins using conventional flow cytometry (Figure 1A). However, we found that if we apply a spectral flow cytometer, 23 then we can distinguish between the four fluorophores based on their spectral shape. Simultaneous detection of Fucci and KikGR signals. (A) Fluorescence spectrum diagrams of KikGR-Green, KikGR-Red, and Azami Green (mAG), Kusabira Orange (mKO). (B) Lymphocytes isolated from lymph nodes of Fucci/KikGR mice were cultured in concanavalin A containing medium for 2 d. Half of the cells were exposed to violet light to photoconvert KikGR color from KikGR-Green to KikGR-Red and were mixed with the remaining non-photoconverted cells and analyzed by spectral flow cytometer. Nuclei of individual Fucci-expressing cell in G1/G0 phase express mKO and in S/G2/M phase express mAG. Representative plots of Fucci-mKO and mAG signals (left), KikGR-Green and Red (center) signals, and the signals of Fucci-mKO and mAG (right) in KikGR-Green+ and KikGR-Red+ cells are shown. Values in the plots indicate the percentage of the parent population. We first used this approach to test whether we could distinguish these four fluorescent signals simultaneously in KikGR/Fucci mice in which KikGR and Fucci proteins are in the same cell. Proliferating lymphocytes from KikGR/Fucci mice were prepared by concanavalin A stimulation of lymphocytes obtained from LNs of KikGR/Fucci mice. For this experiment, half of the cells were exposed to violet light to switch them from KikGR-Green to KikGR-Red. These cells were then pooled with the non-photoconverted fraction and analyzed. We found that KikGR-Green and KikGR-Red cells were easily separated using spectral cytometry. Furthermore, Fucci-signals in KikGR-Green and KikGR-Red populations displayed the same signal pattern (Figure 1B right panel). Taken together, these results demonstrate that spectral cytometry enables reliable discrimination of the four fluorescent proteins with minimal spillover. CD4+ cell depletion enhances CD8+ cell proliferation in tumor dLN In order to evaluate the effect of CD4+ cell depletion on migration and proliferation of DCs, MC38 mouse colon cancer cells were intradermally inoculated into the abdominal skin of the KikGR/Fucci mice on day 0. An anti-CD4 mAb was administered intraperitoneally on day 4, tumors were exposed to violet light to photoconvert tumor-infiltrating cells on day 6, and cells in the dLN were analyzed on day 7 (Figure 2A). At the time of analysis (3 d after mAb administration), CD4+ cells in dLNs remained depleted, while the number of CD8+ cells increased compared to the vehicle control group (Supplementary Figure 1A, B). In addition, Fucci signals in CD8+ cells (which are mainly made up of CD8+ T cells) showed a significant increase in mAG+ cells, which are in S/G2/M phase (Supplementary Figure 1C) in line with a previous report. 7 To ensure reliable flow cytometric analyses, doublets were excluded by FSC/SSC-based gating and singlet discrimination. KikGR positivity was additionally used to minimize dead cell contamination, as KikGR fluorescence rapidly diminishes upon cell death (Supplementary Figure 3). CD4+ cell depletion increases cell number, proportion in migratory DCs, and MHC class II expression of tumor derived KikGR-Red migratory DCs in dLNs. (A) Experimental setup for the analysis of Ti-DC migration to dLN. MC38 were intradermally inoculated in the abdominal skin. Four days later, anti-CD4 mAb was intraperitoneally injected. Six days after tumor inoculation, cells in the tumor were photoconverted by exposure to violet light, and 24 h later, cells in tumor and dLNs were analyzed. (B) Representative plots of KikGR-Green and KikGR-Red signals of cells isolated from tumors of non-photoconverted (upper left panel) and photoconverted (upper right panel) KikGR/Fucci mice, and an inguinal dLN (lower right panel) immediately after photoconversion. (C) Representative KikGR signal expression in CD11c+MHC class IIhigh migratory DCs. (Upper). Numbers and proportion of KikGR-Red DCs in migratory DCs (lower). (D) Representative Fucci signal expression (Upper). Numbers and proportion of mAG+ DCs in KikGR-Red migratory DCs (lower). (E) Representative MHC class II expression and summarized MFI in KikGR-Red migratory DCs. Data in graphs represents means ± SEM (n = 14–18 [C, D], n = 6–8 [E]). **p < 0.01 and ***p < 0.001 (Mann–Whitney U test). Identical KikGR-Green and KikGR-Red axis ranges and gating boundaries were applied across all experimental groups for the analyses shown in panels B and C. For Fucci analyses (panel D), identical gating strategies were applied within each panel. CD4+ cell depletion enhances tumor-infiltrating DC migration to dLN Since CD4+ cell depletion enhanced CD8+ T cell proliferation, we hypothesized that this effect might be explained by quantitative and qualitative changes in DCs. We therefore investigated whether DC migration from tumor to dLN was altered following treatment by photoconverting tumor-infiltrating immune cells in KikGR mice. When analyzed immediately after photoconversion, almost all the cells in tumors were photoconverted to KikGR-Red, while the cells in the tumor dLNs were KikGR-Green (Figure 2B). Twenty-four hours later, we detected KikGR-Red cells among CD11cint MHC class IIhigh migratory DCs, but not in CD11chigh MHC class IIint LNDCs in dLNs (Supplementary Figure 3B) in line with our previous results. 18 Notably, both the number of KikGR-Red migratory DCs and the proportion of KikGR-Red cells in migratory DCs in dLNs significantly increased following CD4+ cell depletion (Figure 2C). It is possible that increased migration as well as proliferation contribute to the increase in KikGR-Red DCs in dLN. To investigate whether proliferation is contributing to the increase in migratory DC number, we assessed the Fucci signal in KikGR-Red migratory DCs to determine the cell cycle phase. In the Fucci (SA) system, mKO2 (hCdt1) marks the G0/G1 compartment, with signal intensity providing additional resolution. As previously reported, mKO2 accumulates during G1 and further increases after cell-cycle exit, such that quiescent G0 cells exhibit the highest signal, whereas cycling G1 cells show lower levels. Rapidly cycling cells may also enter S phase before sufficient mKO2 accumulation. Accordingly, we interpret mAG (hGeminin) positivity as S/G2/M and use mKO2 intensity to distinguish quiescent G0 from cycling G1 cells. 21 , 22 Our analysis showed that almost all of the migratory DCs expressed high levels of mKO2 (indicating G0 phase) and few were mAG+ regardless of whether the mice received anti-CD4 mAb treatment. This indicates that KikGR-Red DCs show little or no proliferation (Figure 2D). These results suggested that CD4+ cell depletion promotes migration of migratory DCs from tumors to dLNs but not their proliferation. Next, we evaluated whether CD4+ cell depletion induces activation-associated phenotype characterized by increased MHC class II expression of migratory DCs. 24 We observed that MHC class II expression was increased in tumor-egressing KikGR-Red DCs in dLNs in anti-CD4 mAb-treated mice compared to the vehicle control group (Figure 2E and Supplementary Figure 4). In addition, CD4+ cell depletion promoted migration from tumors to dLNs and increased in MHC class II expression in both migratory CD11b– CD103+ and CD11b+ CD103– cells (Supplementary Figure 6). Migratory CD11b– CD103+ DCs predominantly expressed cDC1 marker, XCR1 25 (Supplementary Figure 5). These results suggest that CD4+ cell depletion improves both quantity and quality of migratory DCs by enhancing their migration and activation-associated phenotype. Overall immune composition in tumor dLNs following CD4 depletion Before focusing on LNDCs, we assessed broader immune alterations in tumor dLNs. Immune profiling was performed at d6 (photoconversion initiation) and d7 (final analysis) (Figure 2A), quantifying absolute cell numbers and relative frequencies of major immune populations (Supplementary Figure 2). Immune composition was largely comparable between time points. CD4 depletion reduced total LN cellularity, including T and B cells, while migratory DCs showed a tendency toward reduced absolute numbers. In contrast, LNDC numbers were relatively maintained, resulting in increased relative LNDC frequencies among CD45⁺ leukocytes. These findings indicate that subsequent DC alterations are unlikely to reflect global changes in LN cellularity. CD4+ cell depletion leads to an increase in LNDC number and enhanced activation-associated phenotype To further characterize the LNDC compartment, we next examined LNDC subset composition and activation status in greater detail. In the experimental setting used for the subsequent analyses, reassessment of LNDC numbers showed only a modest increase after CD4+ cell depletion (Figure 3A). CD4+ cell depletion increases cell number of CD11b+CD8α+ LNDCs and enhanced maturation of cDC1, cDC2, and CD11b+ CD8α+ LNDC subsets. Tumor-bearing KikGR/Fucci mice were treated with vehicle or anti-CD4 mAb, photoconversion of tumor, and analyzed dLN 24 h later as shown in Figure 2A. (A) Summarized cell number of CD11chigh MHC class II+LNDCs. (B) Representative CD11b and CD8α expression in CD11chighMHC class II+LNDCs (left) and proportion of LNDC subsets (right) in total LNDCs. (C) Summarized cell number and (D) MHC class II MFI in LNDC subsets. Data in graphs represents means ± SEM. (n = 14–18 [A, B, C], n = 6–8 [D]). *p < 0.05 and **p < 0.01 (Mann–Whitney U test). We then analyzed MHC class IIint CD11chigh LNDC subsets as previously. 18 In uninflamed subcutaneous LNs, LNDCs are subdivided into CD11b+ cDC2 and CD8α+ cDC1. 15 Consistent with established definitions, CD8α⁺ LNDCs predominantly expressed XCR1, whereas CD11b⁺ LNDCs were largely SIRPα⁺ 25 (Supplementary Figure 5). However, in tumor-inoculated mice, especially after CD4+ cell depletion, we observed a substantial CD11b+ CD8α+ LNDC population in addition to cDC1 and cDC2 LNDCs. To account for this, LNDCs were subdivided into four subsets: cDC1, cDC2, CD11b+ CD8α+, and CD11b– CD8α– (double negative: DN) (Figure 3B). We found that the proportion of cDC2 among total LNDCs was decreased, while that of CD11b+ CD8α+ DCs increased in CD4+ cell-depleted mice. In addition, CD4+ cell depletion increased the number of CD11b+ CD8α+ DCs (Figure 3C) and expression of MHC class II in cDC1, cDC2, and CD11b+ CD8α+ DCs (Figure 3D). These results indicate that CD4+ cell depletion increases both the number and activation-associated phenotype of CD11b+ CD8α+ LNDC subset, in addition to cDC1 LNDCs. CD4+ cell depletion enhances influx and proliferation of LNDCs An increase in the number of LNDCs after CD4+ cell depletion could be due to an increase in cell influx and/or cell proliferation. To clarify the contribution of these, we photoconverted dLNs instead of tumors using the same protocol as in Figure 2A. Since all LNDCs in dLNs were photoconverted to KikGR-Red by exposure to violet light (Supplementary Figure 7), the cells that were KikGR-Red at the time of analysis remained in dLNs for longer than 24 h, while KikGR-Green cells were newly recruited to dLNs (Figure 4A). CD4+ cell depletion enhances influx and proliferation of LNDCs in dLNs. MC38 cells were intradermally inoculated into the abdominal skin. Four days later, anti-CD4 mAb was administered intraperitoneally. Six days after tumor inoculation, tumor dLNs were photoconverted by exposure to violet light and cells in dLNs were analyzed 24 h later. (A) Experimental setup for the analysis of LNDC turnover in tumor dLNs is shown. (B) The number of total LNDCs. (C) Representative KikGR-Green/Red and mKO2/mAG signals in LNDCs. (D) Proportions of KikGR-Green and KikGR-Red cells in total LNDCs. (E) The number of KikGR-Green and KikGR-Red LNDCs. (F) and (G) Proportions (F) and the numbers (G) of mAG+ cells in total LNDCs. (H) and (I) Proportions (H) and the number (I) of mAG+ cells in KikGR-Green and KikGR-Red cells. Data in graphs represent means ± SEM (n = 8–9). *p < 0.05, **p < 0.01, and ***p < 0.001 (Mann–Whitney U test). As also observed in a separate experiment (Figure 3A), the number of LNDCs per LN showed a modest increase in CD4+ cell-depleted mice (Figure 4B). Twenty-four hours after photoconversion, about 9% of LNDCs in vehicle-treated group were KikGR-Green, representing newly recruited cells. However, after anti-CD4 treatment, 17% of LNDCs were KikGR-Green (Figure 4C and D). When comparing by cell numbers, the number of KikGR-Red LNDCs tended to increase, while the KikGR-Green LNDCs significantly increased in anti-CD4 mAb-treated mice (Figure 4E). These results suggested that the increase in LNDC number upon CD4+ cell depletion was due to an increase in both dLN-remaining and newly recruited LNDCs. To examine whether the increase in LNDC number was due to enhanced cell cycle activity, we investigated LNDC cell cycle phase by quantitating the proportion of mAG+ (cells in S/G2/M phase) cells. Although the proportion of mAG+ cells was not altered, the total number of mAG+ LNDCs increased slightly (Figure 4C, F and G). However, when divided into KikGR-Green and KikGR-Red cells, KikGR-Green cells tended to be more proliferative than KikGR-Red cells and the proportion of mAG+ cells in KikGR-Green cells was significantly higher than in KikGR-Red cells after CD4+ cell depletion (Figure 4C and H). In addition, the number of mAG+ KikGR-Green cells was significantly increased after CD4+ cell depletion (Figure 4I). These results indicate that CD4+ cell depletion increased proliferation in newly recruited LNDCs. Although we cannot exclude the possibility that KikGR-Green cells contain some proliferating KikGR-Red cells that diluted the red signal due to proliferation, their number would be very small and would not substantially affect our calculations. CD4+ cell depletion enhances influx and proliferation of CD11b+ CD8α+ and CD8α+ LNDCs As shown above, we found that higher total LNDC numbers in anti-CD4 mAb-treated mice were due to their increased replacement and proliferation (Figure 4). Here we applied similar analysis to test whether this was also true for specific LNDC subsets. In all four (DN, cDC1, cDC2, and CD11b+ CD8α+) LNDC subsets, both the numbers and proportions of newly recruited KikGR-Green LNDCs increased in the CD4+ cell-depleted mice (Figure 5A and B). For dLN-remaining KikGR-Red cells, the number of cells in the CD11b+CD8α+ LNDC subset also increased after CD4+ cell depletion. Analysis of cell cycle phase in KikGR-Green cells showed that the number and proportion of cells in S/G2/M phase (mAG+ cells) among CD11b+CD8α+ LNDCs and DC1s significantly increased in the CD4+ cell-depleted group (Figure 5C and D). Together, these results indicate that CD4+ cell depletion elicits increased recruitment and proliferation of LNDCs into dLNs, especially cDC1 and CD11b+ CD8α+ LNDCs. Notably, for the CD11b+ CD8α+ KikGR-Red dLN-remaining LNDCs, the number of mAG+ cells also increased, suggesting that CD11b+ CD8α+ LNDCs continue to proliferate for a longer time compared to other LNDC subsets. CD4+ cell depletion enhances influx and proliferation of CD11b+CD8α+ LNDCs and cDC1s in dLNs. LNDCs indicated in Figure 4 were subdivided into DN, cDC1, cDC2, and CD11b+ CD8α+ LNDC subsets. (A) Proportions of KikGR-Green cells in each subset. (B) The numbers of KikGR-Green and KikGR-Red cells in each LNDC subset. (C) and (D) The proportion (C) and numbers (D) and of mAG+ cells in KikGR-Green and KikGR-Red cells in each LNDC subset. Data in graphs represents means ± SEM (n = 8–9). *p < 0.05, **p < 0.01, and ***p < 0.001 (Mann–Whitney U test). CD8β+ cell depletion does not alter DC migration from tumors to dLNs and LNDC proliferation We observed an increase in migratory DCs and CD11b+CD8α+ LNDC subsets and enhanced maturation in both of these subsets in tumor dLNs in CD4+ cell-depleted mice. To investigate whether these changes were partly attributable to the inflammation induced by the massive cell death or to the removal of CD4+ cells that suppress DC activity, we depleted CD8+ T cells using a depleting antibody to induce their death. Mouse DCs express a homodimer of CD8α chains, while CD8+ T cells express a heterodimer of CD8α and β chains. 26 Therefore, anti-CD8β mAb was administered to deplete CD8+ T cells. Seventy-two hours following anti-CD8β mAb administration, CD8+ T cells in the inguinal tumor dLN were significantly reduced (Figure 6A). However, we observed no significant changes in KikGR-Red migratory DCs in CD8β+ cell-depleted mice in terms of proportion, cell number, and MHC class II expression, as well as cell number and proportion of mAG+ cells (Supplementary Figure 8). Moreover, there were no significant differences in the proportion, cell number, and MHC class II expression, proportion in LNDC subsets, and cell number of mAG+ cells among all four (DN, cDC1, cDC2, and CD11b+ CD8α+) LNDC subsets (Figure 6B–D). These results suggest that the qualitative and quantitative enhancement in migratory DCs and LNDCs following anti-CD4 mAb treatment is specifically due to the effect of removing CD4+ cells. CD8β+ cell depletion did not enhance LNDC composition, proliferation, and migration. MC38 were intradermally inoculated in the abdominal skin of KikGR/Fucci mice. Four days later, anti-CD8β mAb was intraperitoneally injected, and 3 d later, tumor dLNs were analyzed. 2(A) Representative flow cytometry plots (left) and numbers of MHC class II– CD8α+ cells in dLNs (right). (B) Representative CD8α and CD11b expression in LNDCs (left) and proportion of LNDC subsets in total LNDCs (right). (C) Numbers of total and mAG+ cells in each LNDC subset. (D) MHC class II MFI in each LNDC subset. Data in graphs represent means ± SEM (n = 10–14 [A, B, C], n = 6[D]). CD4+ cell depletion is associated with increased Flt3l and Csf2 mRNA expression in tumor dLN LNDCs are maintained by growth factors, such as FLT3L 27 and GM-CSF, 28 which regulate their differentiation and maturation. qPCR analysis revealed increased Flt3l expression and a trend toward higher Csf2 levels in tumor dLNs 24 h after CD4 depletion, whereas no changes were observed following CD8β depletion (Supplementary Figure 9). These findings suggested the possibility of altered growth factor signaling within the LN microenvironment. In order to narrow down the cellular sources, we next analyzed a publicly available single-cell RNA sequencing dataset derived from tumor dLNs in a subcutaneous melanoma model. 29 Flt3l transcripts were detectable across multiple LN–resident populations, including stromal compartments, such as fibroblasts and endothelial cells, as well as selected immune subsets (Figure 7A, Supplementary Table 3, and Supplementary Figure 10). Violin plot analysis further demonstrated that Flt3l expression was distributed across a broad fraction of cells within these populations, rather than being driven by a small number of highly expressing outlier cells (Figure 7B). Single-cell RNA-seq–based distribution of Flt3l–Flt3 and Csf2–Csf2r-related transcripts in tumor dLNs. (A) Dot plot of Flt3l, Csf2, Flt3, Csf2ra, and Csf2rb expression across LN cell subsets in a publicly available scRNA-seq dataset. Dot size represents the percentage of cells expressing Flt3l within each subset, and color intensity indicates average expression level (raw values). Cell subsets represented by fewer than 30 cells were excluded from quantitative analyses to ensure robustness. An overview of all annotated cell subsets and their representation in the dataset is provided in Supplementary Figure 10. (B) Violin plots showing the distribution of Flt3l expression across representative lymph node cell subsets. Each dot represents an individual cell. Cell subsets with fewer than 30 cells were excluded. (C) Violin plots showing expression of Flt3, Csf2ra, and Csf2rb in migratory DC, cDC1, and cDC2. Each dot represents an individual cell. Gene expression levels are shown as raw log-normalized values. In contrast, Flt3 expression was enriched in DC subsets, including cDC1 and cDC2, and migratory DCs (Figure 7C). Csf2ra and Csf2rb showed similar DC-biased expression patterns. Together, these data provide transcriptional context indicating that the qPCR-detected changes are consistent with known ligand–receptor expression patterns within the LN microenvironment. Discussion In this study, we established and applied the KikGR/Fucci system to simultaneously detect cellular movement and cell cycle phase in vivo. Our analysis revealed that CD4+ cell depletion promoted activation-associated phenotypic changes in migratory DCs, as well as their migration from tumors to dLNs. In the tumor microenvironment, immunosuppressive CD4+ cells, such as Tregs, inhibit maturation of tumor-infiltrating DCs via cell surface molecules, such as CTLA-4 and LAG3, and release of cytokines, such as IL-10 and TGF-β 30‐32 ; hence, CD4+ cell depletion canceled inhibition of migratory DCs. The treatment also led to an increase in the number of LNDCs in dLNs and induced recruitment and proliferation of CD8α+ cDC1 and CD11b+ CD8α+ LNDCs within dLNs. 27 , 28 , 30 In addition to CD4+ T cells, CD4 expression has also been reported on various other immune and non-immune cells, including macrophages, a subset of monocytes, DCs and Langerhans cells, B cells, brain microglial cells, 33 invariant natural killer T cell, 34 and plasmacytoid DCs. 35 However, since T cells are known to be the predominant CD4-expressing population efficiently targeted by anti-CD4 antibodies, we consider CD4+ T cells, including Tregs, to be the main targets of CD4+ cell depletion. 7 , 34 , 35 CD4+ T cells, including Tregs, are known to move bidirectionally between inflammatory tissues and dLNs, 36 , 37 and tumor-egressing T cells can migrate to dLNs. 38 Similarly, tumor Tregs may migrate to dLNs and suppress maturation of LNDCs, and this suppression may be lifted by anti-CD4 mAb administration. However, anti-CD25–mediated Treg depletion produced only a modest effect, whereas complete CD4⁺ T cell depletion markedly suppressed tumor growth. 7 Moreover, CD4⁺ T cell removal, but not Foxp3-targeted Treg depletion, increased cDC1 frequency and CD86 expression in tumor dLNs. 39 These findings suggest that the strong anti-tumor effect of CD4⁺ T cell depletion is not explained by Tregs alone but also involves other CD4⁺ T cell subsets. CD4+ cell depletion increased the number of LNDCs in dLNs and promoted recruitment and proliferation of cDC1 within dLNs. Because cDC1 LNDCs can receive tumor antigens from migratory cDC1 and cross present it to CD8+ T cells, 15 cDC1 LNDCs may contribute to enhancement of antigen presentation to CD8+ T cells. We identified a CD8α⁺CD11b⁺ LNDC population in tumor dLNs, a substantial fraction of which exhibited cDC1-associated features by XCR1 expression. This subset showed dynamic abundance and active cell-cycle progression, suggesting an activation-associated LNDC subset within the LN microenvironment. These cells may participate in antigen presentation under enhanced immune activation, such as after CD4⁺ cell depletion, although their functional role requires further investigation. Therefore, CD4+ cell depletion can enhance antigen presentation to CD8+ T cells via the indirect presentation pathway by increasing the number of these LNDC subsets. Flt3L and GM-CSF are involved in DC differentiation, proliferation, and homeostasis in LNs. 40 In particular, Flt3-Flt3L signaling regulates proliferation of DCs in peripheral lymphoid tissue in the steady state. 41 Macrophages, mast cells, endothelium, fibroblasts, and T cells have been shown to produce GM-CSF within LNs, 42 , 43 while CD4+ T cells, CD8+ T cells, and cDC2s are known as a source of Flt3L in LNs. 44‐46 In the present study, depletion of CD4+ cells, but not CD8+ T cells, was associated with a tendency toward increased Flt3L and Csf2 mRNA expression in tumor dLNs. These observations raise the possibility that altered production of these growth factors contributes to the enhanced accumulation and proliferative activity of LNDCs following CD4⁺ cell depletion. Consistent with scRNA-seq–based expression patterns in tumor dLNs, Flt3L, and GM-CSF may act within the LN microenvironment, where their receptors are preferentially expressed by DC subsets. Together, these findings suggest that CD4⁺ cell depletion may modify the growth factor milieu of the dLN in a manner permissive for DC expansion and activation-associated changes. How these pathways influence DC dynamics in tumor dLNs remains an important question for future investigation. In this study, using a novel cell-tracking system, we demonstrated that anti-CD4 antibody treatment promotes the migration and maturation of tumor-derived migratory DCs to dLNs, as well as the proliferation and recruitment of LNDC subsets, accompanied by the induction of DC growth factors. However, the precise mechanisms by which CD4⁺ T cells regulate DC migration and the expression of growth factors remain to be elucidated. Elucidating these mechanisms may enable the development of new therapeutic strategies that can promote DC migration and proliferation in a manner similar to CD4 depletion. Although PBS-treated mice were used as controls in the present study, we acknowledge that inclusion of an isotype control antibody could have provided additional context for distinguishing CD4⁺ cell depletion-specific effects from potential non-specific antibody-mediated immunomodulatory effects. The tumor dLN is an important site for initiating adaptive antitumor immunity. Here we showed how CD4+ cell depletion can be used to enhance anti-tumor immune responses by modulating migratory DC and LNDC kinetics, an important determinant of anti-tumor-specific CD8+ T cell activation in the tumor dLNs. While migratory cDC1 have been extensively studied as key mediators of anti-tumor immunity, our findings indicate that LNDCs should also be investigated in greater detail to understand their immunological potential. Supplementary Material Supplementary Information_260421.docx Supplementary Information_260421.docx ARRIVEguidelines_AuthorChecklist ARRIVEguidelines_AuthorChecklist Acknowledgments Taiki Moriya, Mizuki Ueda, Hiroaki Hemmi, Tsuneyasu Kaisho, Satoshi Ueha, Koji Matsushima, Yutaka Kusumoto, and Michio Tomura designed experiments. Taiki Moriya, Mayuko Hashimoto, Yutaka Kusumoto, Mizuki Ueda, Tatsuya Aoyagi, Ayako Kawaguchi, Kentaro Takahashi, Tsukasa Kobayashi, Kazuki Doi, and Michio Tomura performed experiments. Taiki Moriya, Mayuko Hashimoto, and Michio Tomura analyzed data. Mayuko Hashimoto and Michio Tomura performed computational analyses of publicly available scRNA-seq datasets. Taiki Moriya, Mayuko Hashimoto, Mizuki Ueda, Tatsuya Aoyagi, Ayako Kawaguchi, Kentaro Takahashi, Tsukasa Kobayashi, Kazuki Doi, Hiroaki Hemmi, Tsuneyasu Kaisho, Satoshi Ueha, Koji Matsushima, Yutaka Kusumoto, Tatyana Chtanova, and Michio Tomura wrote the manuscript. All authors agreed to be responsible for the content of the work. Funding Statement This work was supported in part by JSPS Grants-in-Aid for Scientific Research in JSPS Grants-in-Aid for Scientific Research (B) [#16H05087]; JSPS Grants-in-Aid for Scientific Young Scientists [#18K14598]; the National Breast Cancer Foundation [IIRS-22-053] to T.C., inter-disciplinary funding scheme grants, and ARC Discovery Project Grant [DP220102278] to T.C. Disclosure statement No potential conflicts of interest were disclosed. Data availability statement The data generated in this study are available in the article and its Supplementary Materials or upon request from the corresponding author. Ethics approval All experimental procedures were approved by the Institutional Animal Care and Use Committee of Osaka Ohtani University Faculty of Pharmacy. Provenance and peer review Not commissioned; externally peer reviewed. Ethics statement Not applicable. Patient consent for publication Not applicable. Supplementary material Supplemental data for this article can be accessed at https://doi.org/10.1080/2162402X.2026.2682054. References Associated Data Supplementary Materials Supplementary Information_260421.docx Supplementary Information_260421.docx ARRIVEguidelines_AuthorChecklist ARRIVEguidelines_AuthorChecklist Data Availability Statement The data generated in this study are available in the article and its Supplementary Materials or upon request from the corresponding author.